AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MDWD

SHAMIR NACHUM purchased $84K of MDWD

SHAMIR NACHUM purchased 6,000 shares of MediWound Ltd. (MDWD) at an average of $14.00 ($13.98–$14.00) across 2 trades on 2026-06-03.

Original reporting
SEC EDGAR · SHAMIR NACHUM
Published Jun 4, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDWD
Neutral
low confidence
Mentioned
$MDWD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDWDNeutralLow
01

Why it matters

The director's purchase is a primary disclosure but the amount is small, offering limited trading insight.

02

Market read

Minor insider buy; unlikely to move the stock significantly.

03

Timing

after-hours filing on June 4

Relevance 4/10Novelty 4/10Timing: after-hours filing on June 4

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$MDWDNeutralLow confidence
Context

Director Shamir Nachum purchased 6,000 shares of MediWound Ltd. for $83,996.

Expected impact

slight upward pressure as market prices in insider confidence

Evidence & confidence

Purchase size (~$84K) is modest relative to market cap; typical insider buys have limited immediate effect.

Key entities

  • Company
    MediWound Ltd.

    Biotech company listed under ticker MDWD.

  • Individual
    Shamir Nachum

    Director of MediWound Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDWD insider trading history →

Related articles

$MDWDMed

A sale of 1.2 million MediWound shares is expected to close around Nov. 5.

MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.

stocktitan.net
$MDWDHighAI 8/10

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)

MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.

investegate.co.uk
$MDWDMed

MediWound Ltd. (MDWD): Financial results for Q2 2026

MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it

SEC EDGAR 6-K